U.S. Markets closed

Johnson & Johnson Is a Defensive Stock. Now There’s Hope for Growth.

Josh Nathan-Kazis

Sales at Johnson & Johnson ‘s pharmaceutical business are poised to surge to $50 billion by 2023—a leap of more than 20%.